AstraZeneca’s Brilinta Gives Brilliant Sales Performance
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.